我們已在上線！進一步了解

CDT Equity Inc

CDT

市值 US$18.1萬

0.2351 USD

+0.0261

12.49%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.2028

-0.0323

13.74%

1天

12.49%

5天

-66.52%

1個月

-95.25%

3個月

-99.74%

6個月

-99.97%

今年迄今

-100%

1年

-100%

5年

-100%

10年

-100%

關於： CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

員工： 4

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually.

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Equity Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

CDT Equity Inc. Announces Reverse Stock Split

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds.

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”).

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company's common stock, subject to shareholder approval at the Company's annual meeting of stockholders on August 28, 2026 (the “Transaction”).

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

查看新聞排名

價格圖表採用Lightweight Charts™實作